Exelixis, Inc.
zanzalintinib
previously treated metastatic colorectal cancer
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for zanzalintinib in previously treated metastatic colorectal cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“planned trial initiations of STELLAR-316 and STELLAR-201 supporting the next wave of zanzalintinib’s pivotal development,”